BITESIZE: New Study: Why Did This Drug Lower Cholesterol But Not Heart Plaque?
Lower triglycerides, lower remnant cholesterol, lower ApoB. Zero change in coronary artery plaque. A new clinical trial is forcing a bigger conversation about how we treat cardiovascular disease.
The drug was Olezarsen, an APOC3 inhibitor. The blood work looked impressive. The heart scans did not. So why would lowering well-established cardiovascular risk factors fail to move the needle on plaque? Dr. Bret Scher argues there's a critical difference between what we want to fix and how we go about fixing it. Lowering a number with a drug is not the same as addressing the underlying metabolic…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.